Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV).

Trial Profile

Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV).

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 May 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms ISAV
  • Most Recent Events

    • 24 Nov 2016 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
    • 24 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2018.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top